natgillin/translations-raw huggingface dataset:
The compound of claim 1, wherein the modified oligonucleotide consists of 18 linked nucleosides having a nucleobase sequence consisting of SEQ ID NO: 11, and wherein the modified oligonucleotide comprises: 
Spoj prema patentnom zahtjevu 1, gdje se modificirani oligonukleotid sastoji od 18 povezanih nukleozida sa sekvencom nukleobaza koja čini SEQ ID NO: 11 i gdje modificirani oligonukleotid sadrži:
The compound of claim 1, wherein the modified oligonucleotide consists of 20 linked nucleosides having a nucleobase sequence consisting of any of SEQ ID NOs: 7, 6, or 8, and wherein the modified oligonucleotide comprises: a gap segment consisting of 10 linked deoxynucleosides; 
Spoj prema patentnom zahtjevu 1, gdje se modificirani oligonukleotid sastoji od 20 povezanih nukleozida sa sekvencom nukleobaza koja čini bilo koju od SEQ ID NO: 7, 6 ili 8 i gdje modificirani oligonukleotid sadrži: segment “razmaka” koji se sastoji od 10 povezanih dezoksinukleozida;
each internucleoside linkage of the modified oligonucleotide is a phosphorothioate linkage; 
svaka internukleozidna veza modificiranog oligonukleotida je fosforotioatna veza;
each internucleoside linkage of the modified oligonucleotide is selected from a phosphodiester internucleoside linkage and a phosphorothioate internucleoside linkage; 
svaka internukleozidna veza modificiranog oligonukleotida je izabrana od fosfodiestarske internukleozidne veze i fosforotioatne internukleozidne veze;
the modified oligonucleotide comprises at least 2 phosphodiester internucleoside linkages; 
modificirani oligonukleotid sadrži najmanje 2 fosfodiestarske internukleozidne veze;
the modified oligonucleotide comprises fewer than 14 phosphorothioate linkages, optionally wherein the modified oligonucleotide comprises fewer than 13 phosphorothioate linkages; or 
modificirani oligonukleotid sadrži manje od 14 fosforotioatnih veza, opcionalno gdje modificirani oligonukleotid sadrži manje od 13 fosforotioatnih veza; ili
the modified oligonucleotide is single-stranded. 
modificirani oligonukleotid je jednolančani.
A sheet (10) for packaging food, comprising 
List (10) za pakiranje hrane, koji sadržava
a second intermediate layer (12) made of metallic material, 
drugi međusloj (12) izrađen od metalnog materijala,
a third layer (13) made of plastic material, on which said second layer (12) is deposited, 
treći sloj (13) izrađen od plastičnog materijala, na koji se nanosi navedeni drugi sloj (12),
an adhesive layer (14) between the first and second layers, characterized in that said third layer (13) is constituted by a film of biodegradable and compostable in less than one hundred and eighty days plastic material, as per European standard EN13432 part 2, adapted for contact with food made of a mixture that comprises 
ljepljivi sloj (14) između prvog i drugog sloja, naznačen time, da se navedeni treći sloj (13) sastoji od filma plastičnog materijala koji je biorazgradiv i kompostabilan za manje od sto osamdeset dana, u skladu s europskim standardom EN13432 dio 2., prilagođen da dođe u kontakt s hranom, koji je izrađen od smjese koja sadržava
a polymer based on a biodegradable and compostable copolyester of petrochemical origin, 
polimer na bazi biorazgradivog i kompostabilnog kopoliestera petrokemijskog podrijetla,
a polymer based on lactic acid of vegetable origin; and said adhesive layer (14) is based on vegetable starches and glucose such as to allow easy manual separation of the first layer (11) from the second layer (12) and the third layer (13). 
polimer na bazi mliječne kiseline biljnog podrijetla; i pri čemu je navedeni sloj ljepila (14) baziran na škrobovima i glukozi povrća, tako da omogućuje lako ručno razdvajanje prvog sloja (11) od drugog sloja (12) i trećeg sloja (13).
The sheet (10) according to claim 1, characterized in that said third layer (13), constituted by said film of biodegradable and compostable plastic material has a density of 1.25 ± 0.1 g/cm3 
List (10) u skladu s patentnim zahtjevom 1, naznačen time, da navedeni treći sloj (13), načinjen od navedenog filma biorazgradivog i kompostabilnog plastičnog materijala, ima gustoću od 1,25 ± 0,1 g / cm3.
The sheet (10) according to the preceding claims, characterized in that said third layer has a minimum thickness of 8 µm (microns), with a grammage of 10 g/m2, and a maximum thickness of 18 µm (microns), with a grammage of 22.5 g/m2. 
Postupak u skladu s prethodnim patentnim zahtjevima, naznačen time, da navedeni treći sloj ima debljinu od najmanje 8 um (mikrona), s težinom po jediničnoj površini od 10 g / m2, i maksimalnom debljinom od 18 pm (mikrona), s težinom po jediničnoj površini od 22,5 g / m2.
The sheet (10) according to the preceding claims, characterized in that said third layer (13) is provided by a mixture that also comprises additives designed to modify the color and technical characteristics, maintaining its biodegradability, compostability and suitability for contact with food. 
List (10) u skladu s prethodnim patentnim zahtjevima, naznačen time, da se navedeni treći sloj (13) sastoji od smjese koja također sadržava aditive namijenjene za modificiranje boje i tehničkih svojstava, zadržavajući svoju biorazgradivost, kompostabilnost i prikladnost za kontakt s hranom.
The sheet (10) according to the preceding claims, characterized in that said second intermediate layer (12) made of metallic material is constituted by a thin layer of metallic vapors deposited on said third layer (13). 
List (10) u skladu s prethodnim zahtjevima, naznačen time, da se navedeni drugi međusloj (12) izrađen od metalnog materijala sastoji od tankog sloja metalnih para koje su nanesene na navedeni treći sloj (13).
wherein the entropy decoding unit is further configured for determining positions of the entry points based on an offset which is 1 larger than a number indicated by fourth information obtained from the bitstream; 
određivanje položaja ulaznih točaka na temelju pomaka koji je 1 veći od broja naznačenog četvrtom informacijom dobivenom iz toka bitova; dekodiranje trenutne slike na temelju pohranjenih varijabli konteksta i ulaznih točaka.
An immunoconjugate formulation comprising: 
Formulacija imunokonjugata koja sadrži:
0.01% (w/v) polysorbate 80 wherein the formulation is a buffered aqueous solution having a pH of 5.5. 
% (m/v) polisorbata 80 naznačena time što je formulacija puferirana vodena otopina koja ima pH od 5.5.
The lyophilized composition of claim 2 that is to be reconstituted to contain 5 mg/ml MF-T-SPDB-DM4 comprises 0.31 mg L-Histidine, 1.95 mg Glycine, 9.99 mg sucrose, and 0.02 mg polysorbate 80 per mg of the immunoconjugate MF-T-SPDB-DM4. 
Liofilizirani pripravak prema zahtjevu 2 koji se rekonstituira tako da sadrži 5 mg/ml MF-T-SPDB-DM4 koji sadrži 0.31 mg L-histidina, 1.95 mg glicina, 9.99 mg saharoze, i 0.02 mg polisorbata 80 po mg imunokonjugata MF-T-SPDB-DM4, nakon rekonstitucije s vodom, takav liofilizirani pripravak ima pH od oko 5.5.
determining positions of the entry points based on an offset which is 1 larger than a number indicated by fourth information obtained from the bitstream; decoding the current picture based on the stored context variables and the entry points. 
određivanje položaja ulaznih točaka na temelju pomaka koji je 1 veći od broja naznačenog četvrtom informacijom dobivenom iz toka bitova; dekodiranje trenutne slike na temelju pohranjenih varijabli konteksta i ulaznih točaka.
The compound for use according to any one of claims 1-2, wherein said drug toxicity or overdose is resulting from opioid administration to a non-dependent patient. 
Spoj za uporabu sukladno patentnom zahtjevu 1, pri čemu navedena toksičnost ili predoziranje lijekom nastaje kao rezultat primjene opioida pacijentu koji nije ovisnik.
The compound for use according to any one of claims 1-2, wherein said compound of Formula I is administered in a daily dose of about 3 to about 20 mg/day. 
Spoj za uporabu sukladno patentnom zahtjevu 1, pri čemu se navedeni spoj primjenjuje u dnevnoj dozi od oko 3 do oko 20 mg/dnevno.
The compound for use according to claim 5, wherein said daily dose is about 10 mg/day. 
Spoj za uporabu sukladno patentnom zahtjevu 4, pri čemu je navedena dnevna doza oko 10 mg/dan.
The compound for use according to claim 1, wherein administration of a compound of Formula I reduces symptoms of drug toxicity or overdose over a period of at least about 15 to about 30 minutes, optionally wherein symptoms of drug overdose are reduced for a period of at least one hour, optionally wherein symptoms of drug overdose are reduced for a period of at least two hours, optionally wherein symptoms of drug overdose are reduced for a period of at least three hours, optionally wherein symptoms of drug overdose are reduced for a period of at least four hours, optionally wherein symptoms of drug overdose are reduced for a period of at least eight hours. 
Spoj za uporabu sukladno patentnom zahtjevu 1, pri čemu primjena spoja smanjuje simptome toksičnosti ili predoziranja lijekom tijekom perioda od najmanje 15 do oko 30 minuta. Spoj za uporabu sukladno patentnom 6, pri čemu su simptomi predoziranja lijekom smanjeni za period od najmanje jednog sata, period od najmanje dva sata, period od najmanje tri sata, period od najmanje četiri sata ili period od najmanje osam sati.
The compound for use according to claim 10, wherein said first opioid receptor antagonist is naloxone, optionally wherein: 
Spoj za uporabu sukladno patentnom zahtjevu 10, pri čemu je prvi antagonist receptora opioida nalokson.
The compound for use according to claim 14, wherein said unmonitored treatment is effective for a period of over one hour. 
Spoj za uporabu sukladno patentnom zahtjevu 19, pri čemu je navedeno nekontrolirano liječenje djelotvorno tijekom razdoblja od preko jedog sata..
a DNA-targeting segment comprising a nucleotide sequence that is complementary to a sequence in the target DNA, and 
segment koji cilja na DNA, koji sadrži nukleotidni slijed komplementaran slijedu u ciljanoj DNA, i
a DNA-targeting segment comprising a nucleotide sequence that is complementary to a sequence in the target DNA, and 
segment koji cilja na DNA, koji sadrži nukleotidni slijed komplementaran ciljanom slijedu u ciljanoj DNA, i
A compound comprising a peptide and a conjugating group, wherein the peptide comprises the amino acid sequence: 
Spoj koji sadrži peptid i konjugiranu skupinu, pri čemu peptid sadrži sekvencu aminokiseline:
is D-arginine, for use in the treatment of hyperparathyroidism or a hypercalcemic disorder. 
je D-arginin, za uporabu za liječenje hiperparatiroidizma ili hiperkalcemičnog poremećaja.
The compound for use of claim 1, wherein the peptide comprises a contiguous sequence of D-amino acid residues. 
Spoj za uporabu prema zahtjevu 1, naznačen time što peptid sadrži susjednu sekvencu ostataka D-aminokiselina.
The compound for use of claim 1 or claim 2, wherein when X2 is D-alanine, X4 is D-arginine, or wherein when X2 is D-arginine, X4 is D-alanine. 
Spoj za uporabu prema zahtjevu 1 ili zahtjevu 2, naznačen time što kada X2 je D-alanin, X4 je D-arginin, ili pri čemu kada X2 je D-arginin, X4 je D-alanin.
The compound for use of any one of claims 1-4, wherein the peptide is 8 to 15 amino acids in length. 
Spoj za uporabu prema bilo kojem od zahtjeva 1-4, naznačen time što peptid ima duljinu od 8 do 15 amino kiselina.
A method of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation; 
Postupak konjugiranja polimera topljivog u vodi na oksidirani dio karbohidrata terapeutskog proteina koji sadrži kontaktiranje oksidiranog dijela karbohidrata s aktiviranim polimerom topljivim u vodi pod uvjetima koji dozvoljavaju konjugaciju;
The method according to claim 2 wherein a solution comprising an initial concentration of the therapeutic protein between about 0.3 mg/ml and about 3.0 mg/ml is adjusted to a pH value between about 5.0 and about 8.0 prior to contacting with the activated water soluble polymer; for example, wherein the initial concentration of the therapeutic protein is about 1.0 mg/ml and the pH is about 6.0. 
Postupak prema zahtjevu 2, pri čemu je otopina koja sadrži početnu koncentraciju terapeutskog proteina između oko 0.3 mg/ml i oko 3.0 mg/ml prilagođena na pH vrijednost između oko 5.0 i oko 8.0 prije kontaktiranja s aktiviranim polimerom topljivim u vodi; na primjer, pri čemu je početna koncentracija terapeutskog proteina oko 1.0 mg/ml i pH je oko 6.0.
The method of claim 2 wherein the conjugating the water soluble polymer to the oxidized carbohydrate moiety of the therapeutic protein is stopped by the addition of a quenching agent selected from the group consisting of L-cysteine, methionine, glutathione, glycerol, sodium meta bisulfite (Na2S2O5), tryptophane, tyrosine, histidine or derivatives thereof, kresol, imidazole, and combinations thereof; 
Postupak prema zahtjevu 2, pri čemu se konjugiranje polimera topljivog u vodi na oksidirani dio karbohidrata terapeutskog proteina zaustavlja dodavanjem agensa za gašenje odabranog od skupine koja se sastoji od L-cisteina, metionina, glutationa, glicerola, natrij meta bisulfita (Na2S2O5), triptofana, tirozina, histidina ili njegovih derivata, krezola, imidazola, i njihovih kombinacija;
The method of claim 8 wherein the quenching agent is L-cysteine, and is preferably added to result in a final concentration of about 10 mM and the conditions comprise a time period of about 60 minutes, a temperature of about 22°C, the absence of light and with stirring. 
Postupak prema zahtjevu 8, pri čemu je agens za gašenje L-cistein, i poželjno je dodan kako bi rezultirao krajnjom koncentracijom od oko 10 mM i uvjeti sadrže vremenski period od oko 60 minuta, temperaturu od oko 22 °C, odsutnost svjetla i s miješanjem.
a sixth step wherein the conjugating the water soluble polymer to the one or more oxidized carbohydrates of the therapeutic protein in the fifth step is stopped by the addition of a quenching agent selected from the group consisting of L-cysteine, methionine, glutathione, glycerol, Na2S2O5 (sodium meta bisulfite), tryptophane, tyrosine, histidine or derivatives thereof, kresol, imidazole, and combinations thereof; wherein the quenching agent is added to result in a final concentration of about 1 mM and about 100 mM, under conditions comprising a time period between about 5 minutes and about 120 minutes; a temperature between about 2°C and about 37°C; in the presence or absence of light, and with or without stirring. 
šesti korak pri čemu je konjugiranje polimera topljivog u vodi na jedan ili više oksidiranih karbohidrata terapeutskog proteina u petom koraku zaustavljeno dodavanjem agensa za gašenje odabranog od skupine koja se sastoji od L-cisteina, metionina, glutationa, glicerola, Na2S2O5 (natrij meta bisulfit), triptofana, tirozina, histidina ili njegovih derivata, krezola, imidazola, i njihovih kombinacija; pri čemu je agens za gašenje dodan kako bi rezultirao krajnjom koncentracijom od oko 1 mM i oko 100 mM, pod uvjetima koji sadrže vremenski period između oko 5 minuta i oko 120 minuta; temperaturu između oko 2 °C i oko 37 °C; u prisutnosti ili odsutnosti svjetla; i s ili bez miješanja.
The method of claim 10 wherein the initial concentration of the therapeutic protein in the first step is about 1 mg/ml and the pH is about 6.0; 
Postupak prema zahtjevu 10, pri čemu je početna koncentracija terapeutskog proteina u prvom koraku oko 1 mg/ml i pH je oko 6.0;
wherein the final concentration of oxidizing agent in the second step is about 400 µM, and the conditions comprise a time period of about 10 minutes, a temperature of about 22°C, the absence of light and with stirring; 
pri čemu je krajnja koncentracija oksidirajućeg agensa u drugom koraku oko 400 µM, i uvjeti sadrže vremenski period od oko 10 minuta, temperaturu od oko 22 °C, odsutnost svjetla i s miješanjem;
wherein the excess concentration in the third step is about 50 molar excess; wherein the conditions in the third step comprise a time period of about 15 minutes, a temperature of about 22°C, the absence of light and with stirring; 
pri čemu je višak koncentracije u trećem koraku oko 50 molarnog suviška; pri čemu uvjeti u trećem koraku sadrže vremenski period od oko 15 minuta, temperaturu od oko 22 °C, odsutnost svjetla i s miješanjem;
wherein the final concentration of the nucleophilic catalyst in the fourth step is about 10 mM, and the conditions in the fourth step comprise a time period of about 15 minutes, a temperature of about 22°C, the absence of light and with stirring; 
pri čemu je krajnja koncentracija nukleofilnog katalista u četvrtom koraku oko 10 mM, i uvjeti u četvrtom koraku sadrže vremenski period od oko 15 minuta, temperaturu od oko 22 °C, odsutnost svjetla i s miješanjem;
wherein the conditions of incubating the therapeutic protein with the activated water soluble polymer and nucleophilic catalyst in the fifth step comprise a time period of about 2 hours; a temperature of about 22°C; the absence of light; and with stirring; and wherein the quenching agent in the sixth step is L-cysteine; and wherein the L-cysteine is added to result in a final concentration of about 10 mM and the conditions in the sixth step comprise a time period of about 60 minutes, a temperature of about 22°C, the absence of light and with stirring. 
pri čemu uvjeti inkubiranja terapeutskog proteina s aktiviranim polimerom topljivim u vodi i nukleofilnim katalistom u petom koraku sadrže vremenski period od oko 2 sata; temperaturu od oko 22 °C; odsutnost svjetla; i s miješanjem; i pri čemu je agens za gašenje u šestom koraku L-cistein; i pri čemu je L-cistein dodan kako bi rezultirao krajnjom koncentracijom od oko 10 mM i uvjeti u šestom koraku sadrže vremenski period od oko 60 minuta, temperaturu od oko 22 °C, odsutnost svjetla i s miješanjem.
The method according to claim 2 wherein the water soluble polymer is PSA and is comprised of about 10 - 300 sialic acid units. 
Postupak prema zahtjevu 2, pri čemu je polimer topljiv u vodi PSA i sadržan je od oko 10 - 300 jedinica sijalinske kiseline.
The method according to claim 2 wherein when the therapeutic protein is a blood coagulation protein, the oxidized carbohydrate moiety of the therapeutic protein is located in the activation peptide of said blood coagulation protein. 
Postupak prema zahtjevu 2, pri čemu kada je terapeutski protein protein zgrušnjavanja krvi, oksidirani dio karbohidrata terapeutskog proteina je lociran u aktivacijskom peptidu spomenutog proteina zgušnjavanja krvi.
wherein the aminooxy linker is selected from the group consisting of: 
pri čemu je aminooksi veznik odabran od skupine koja se sastoji od:
The method according to any one of claims 1-16 further comprising the step of reducing an oxime linkage in the conjugated therapeutic protein by incubating the conjugated therapeutic protein in a buffer comprising a reducing compound selected from the group consisting of sodium cyanoborohydride (NaCNBH3), ascorbic acid (vitamin C) and NaBH3. 
Postupak prema bilo kojem od zahtjeva 1-16, koji dalje sadrži korak reduciranja vezanja oksima kod konjugiranog terapeutskog proteina inkubiranjem konjugiranog terapeutskog proteina u puferu koji sadrži reduciranje spoja odabranog od skupine koja se sastoji od natrij cijanoborohidrida (NaCNBH3), askorbinske kiseline (vitamin C) i NaBH3.
The method according to any one of claims 1-17 further comprising the step of purifying the conjugated therapeutic protein; for example wherein the conjugated therapeutic protein is purified by a method selected from the group consisting of chromatography, filtration and precipitation. 
Postupak prema bilo kojem od zahtjeva 1-17, koji dalje sadrži korak pročišćavanja konjugiranog terapeutskog proteina; na primjer pri čemu je konjugirani terapeutski protein pročišćen metodom odabranom iz skupine koja se sastoji od kromatografije, filtracije i precipitacije.
The method according to claim 18 wherein the chromatography is selected from the group consisting of Hydrophobic Interaction Chromatography (HIC), Ion Exchange chromatography (IEC), Size exclusion chromatography (SEC), Affinity chromatography, and Reversed-phase chromatography, optionally wherein an anti-chaotropic salt is used in a chromatography loading step and in a chromatography washing step; optionally wherein the chromatography takes place in a column, such as a column comprising a chromatography resin selected from the group consisting of Phenyl-Sepharose FF and Butyl-Sepharose FF; and wherein the resin is preferably present in the column at a bed height of between about 5 cm and about 20 cm, preferably about 10 cm. 
Postupak prema zahtjevu 18, pri čemu je kromatografija odabrana od skupine koja se sastoji od kromatografije hidrofobnih interakcija (HIC), ionoizmjenjivačke kromatografije (IEC), kromatografije isključenjem po veličini (SEC), afinitetne kromatografije i kromatografije reverzne faze, izborno pri čemu je anti-kaotropska sol korištena u koraku punjenja kromatografije i koraku ispiranja kromatografije; izborno pri čemu se kromatografija događa u koloni, kao što je kolona koja sadrži kromatografsku smolu odabranu od skupine koja se sastoji od Fenil-Sefaroze FF i Butil-Sefaroze FF; i pri čemu je smola poželjno prisutna u koloni visine sloja od između oko 5 cm i oko 20 cm, poželjno oko 10 cm.
forming an oxime linkage between the oxidized carbohydrate moiety of the therapeutic protein and the activated water soluble polymer containing an active aminooxy group in the presence of a nucleophilic catalyst under conditions allowing formation of said oxime linkage; 
formiranje vezanja oksima između oksidiranog dijela karbohidrata terapeutskog proteina i aktiviranog polimera topljivog u vodi koji sadrži aktivnu aminooksi skupinu u prisutnosti nukleofilnog katalista pod uvjetima koji dozvoljavaju formiranje spomenutog vezanja oksima;
forming a hydrazone linkage between the oxidized carbohydrate moiety of the therapeutic protein and the activated water soluble polymer containing an active hydrazide group in the presence of a nucleophilic catalyst under conditions allowing formation of said hydrazone linkage; 
formiranje vezanja hidrazida između oksidiranog dijela karbohidrata terapeutskog proteina i aktiviranog polimera topljivog u vodi koji sadrži aktivnu hidrazid skupinu u prisutnosti nukleofilnog katalista pod uvjetima koji dozvoljavaju formiranje spomenutog vezanja hidrazida;
purifying the water soluble polymer containing an active aminooxy group by a method selected from the group consisting of chromatography, filtration and precipitation. 
pročišćenje polimera topljivog u vodi koji sadrži aktivnu aminooksi skupinu postupkom odabranim od skupine koja se sastoji od kromatografije, filtracije i precipitacije.
The method according to any one of claims 28-32 wherein the aminooxy linker is selected from the group consisting of: 
Postupak prema bilo kojem od zahtjeva 28-32, pri čemu je aminooksi veznik odabran od skupine koja se sastoji od:
The method according to any one of claims 29 and 30 wherein the reducing agent is selected from the group consisting of sodium cyanoborohydride (NaCNBH3), ascorbic acid (vitamin C) and NaBH3. 
Postupak prema bilo kojem od zahtjeva 29 i 30, pri čemu je reducirajući agens odabran od skupine koja se sastoji od natrij cijanoborohidrida (NaCNBH3), askorbinske kiseline (vitamin C) i NaBH3.
An isolated JC-virus neutralizing monoclonal antibody against JCV capsid protein VP1 (JCV-VP1), wherein said monoclonal antibody comprises: 
Monoklonsko protutijelo koje neutralizira izolirani virus JC, usmjereno protiv proteina VP1 iz kapside JCV (JCV-VP1), naznačeno time što navedeno monoklonsko protutijelo ima:
The antibody according to any one of the preceding claims, for use in a method of treating a subject having one or more signs or symptoms of progressive multifocal leukoencephalopathy (PML), or having PML. 
Protutijelo u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time što je namijenjeno upotrebi u postupku liječenja subjekta s jednim ili više znakova ili simptoma progresivne multifokalne leukoencefalopatije (PML) ili koji ima PML.